StockpollyBeta
Get App
Delisting riskPopularity #3,538
PDSB · NASDAQ · Biotechnology

PDS Biotechnology (PDSB)

Develops investigational immunotherapies for cancer and infectious diseases.

$0.8415
vs last close−0.07 (−7.53%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
1110109107988776
Research & development677575645433
43343333423,0643
Selling & marketing000000000000
General & administrative43343033423,0643
Other expenses0—00000000−3,0610
Operating income−11−10−10−9−10−7−9−8−8−7−7−6
00−1−1−1−1−1−2−1−1−1−3
Interest income111111000000
Interest expense111111121113
Other non-operating income−1−1−1−1−1−1000000
Income before tax−11−11−11−9−11−8−10−9−9−8−7−10
Income tax expense000−100−100000
Net income from continuing operations−11−11−11−8−11−8−8−9−9−8−7−10
Net income−11−11−11−8−11−8−8−9−9−8−7−10
EPS, basic−$0.35−$0.34−$0.30−$0.23−$0.29−$0.22−$0.21−$0.21−$0.19−$0.14−$0.13−$0.18
EPS, diluted−$0.35−$0.34−$0.30−$0.23−$0.29−$0.22−$0.21−$0.21−$0.19−$0.14−$0.13−$0.18
Weighted average shares, basic313235373736414647465556
Weighted average shares, diluted313235373736414647465556
EBITDA−10−10−9−8−10−7−9−7−8−6−6−6
Depreciation & amortization000000000000
EBIT−10−10−9−8−10−7−9−7−8−6−6−6